ATE484201T1 - Verwendung von beta-cryptoxanthin - Google Patents
Verwendung von beta-cryptoxanthinInfo
- Publication number
- ATE484201T1 ATE484201T1 AT05738192T AT05738192T ATE484201T1 AT E484201 T1 ATE484201 T1 AT E484201T1 AT 05738192 T AT05738192 T AT 05738192T AT 05738192 T AT05738192 T AT 05738192T AT E484201 T1 ATE484201 T1 AT E484201T1
- Authority
- AT
- Austria
- Prior art keywords
- cryptoxanthin
- beta
- humans
- animals
- proteins
- Prior art date
Links
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 title abstract 2
- NBZANZVJRKXVBH-ITUXNECMSA-N all-trans-alpha-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CCCC2(C)C)C NBZANZVJRKXVBH-ITUXNECMSA-N 0.000 title abstract 2
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 title abstract 2
- 235000002360 beta-cryptoxanthin Nutrition 0.000 title abstract 2
- 239000011774 beta-cryptoxanthin Substances 0.000 title abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000014616 translation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Pediatric Medicine (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fodder In General (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Feed For Specific Animals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04011743 | 2004-05-18 | ||
| PCT/EP2005/005030 WO2005110122A1 (en) | 2004-05-18 | 2005-05-10 | USE OF β-CRYPTOXANTHIN |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE484201T1 true ATE484201T1 (de) | 2010-10-15 |
Family
ID=34966671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05738192T ATE484201T1 (de) | 2004-05-18 | 2005-05-10 | Verwendung von beta-cryptoxanthin |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20080070980A1 (de) |
| EP (1) | EP1748705B1 (de) |
| JP (2) | JP5145035B2 (de) |
| KR (1) | KR101317976B1 (de) |
| CN (1) | CN1953669B (de) |
| AT (1) | ATE484201T1 (de) |
| DE (1) | DE602005024128D1 (de) |
| ES (1) | ES2351701T3 (de) |
| WO (1) | WO2005110122A1 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2047760A4 (de) * | 2006-07-28 | 2012-07-04 | Unitika Ltd | Orale zusammensetzung, die eine verstärkte absorption von cryptoxanthin ermöglicht |
| US20090118227A1 (en) | 2007-11-07 | 2009-05-07 | Bristol-Myers Squibb Company | Carotenoid-containing compositions and methods |
| JP5688697B2 (ja) * | 2009-09-25 | 2015-03-25 | 国立大学法人愛媛大学 | 免疫蛋白質の産生促進剤 |
| JP5909084B2 (ja) * | 2010-12-15 | 2016-04-26 | アークレイ株式会社 | 安定化βクリプトキサンチン含有水およびその用途 |
| CN102219721B (zh) * | 2011-04-02 | 2013-08-07 | 秦皇岛大惠生物技术有限公司 | 一种含有β-隐黄质的浓缩物的提取方法与采用该方法所得到的浓缩物及其用途 |
| EP2731595B1 (de) * | 2011-07-13 | 2019-09-04 | University Of Georgia Research Foundation, Inc. | Verwendung von xanthophyll-carotenoiden zur verbesserung der sehfähigkeit und der nerveneffizienz |
| SG11201502649WA (en) * | 2012-10-04 | 2015-05-28 | Abbott Lab | Methods for enhancing the effect of egcg on mitigating skeletal muscle loss |
| JP5687682B2 (ja) * | 2012-12-20 | 2015-03-18 | ユニチカ株式会社 | カルシウム吸収促進組成物 |
| CA2898890A1 (en) | 2013-01-24 | 2014-07-31 | Omniactive Health Technologies Ltd. | Beta-cryptoxanthin from plant source and a process for its preparation |
| US20160106776A1 (en) * | 2013-05-31 | 2016-04-21 | Dsm Ip Assets B.V. | Feed supplement and its use |
| WO2016113383A1 (en) * | 2015-01-15 | 2016-07-21 | Dsm Ip Assets B.V. | Method of preventing obesity and cardiovascular problems in poultry |
| WO2016174600A1 (en) | 2015-04-27 | 2016-11-03 | Omniactive Health Technologies Limited | Betacryptoxanthin compositions, processes for preparation and uses thereof |
| CN104906112B (zh) * | 2015-05-20 | 2018-02-23 | 杨克西 | 一种促进蛋白质合成的组合物及其制备方法和用途 |
| JP2019218316A (ja) * | 2018-06-21 | 2019-12-26 | 公立大学法人大阪 | オートファジー活性向上剤 |
| SG10201900604TA (en) | 2019-01-23 | 2020-08-28 | Agency For Science Technology And Research Astarstar | Pre-natal beta-cryptoxanthin benefits children |
| WO2022018162A1 (en) | 2020-07-22 | 2022-01-27 | Dsm Ip Assets B.V. | FORMULATIONS OF NEW β-CRYPTOXANTHIN CRYSTAL FORM, PROCESSES FOR THEIR MANUFACTURE AND THEIR USES |
| WO2022018161A1 (en) | 2020-07-22 | 2022-01-27 | Dsm Ip Assets B.V. | Beta-cryptoxanthin crystal forms, liquid formulations thereof and processes for their manufacture |
| CN115530381A (zh) * | 2022-08-17 | 2022-12-30 | 中南大学 | 预防产前抑郁症的蛋白粉及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6582721B1 (en) * | 1999-09-17 | 2003-06-24 | Alcon, Inc. | Stable carotene-xanthophyll beadlet compositions and methods of use |
| US6902739B2 (en) * | 2001-07-23 | 2005-06-07 | Nutracea | Methods for treating joint inflammation, pain, and loss of mobility |
| US8148431B2 (en) * | 2002-10-25 | 2012-04-03 | Kemin Health, L.C. | Osteogenesis promoter containing β-cryptoxanthin as the active ingredient |
-
2005
- 2005-05-10 KR KR1020067024056A patent/KR101317976B1/ko active IP Right Grant
- 2005-05-10 US US11/596,618 patent/US20080070980A1/en not_active Abandoned
- 2005-05-10 ES ES05738192T patent/ES2351701T3/es active Active
- 2005-05-10 AT AT05738192T patent/ATE484201T1/de not_active IP Right Cessation
- 2005-05-10 WO PCT/EP2005/005030 patent/WO2005110122A1/en not_active Application Discontinuation
- 2005-05-10 JP JP2007517026A patent/JP5145035B2/ja not_active Expired - Fee Related
- 2005-05-10 DE DE602005024128T patent/DE602005024128D1/de active Active
- 2005-05-10 EP EP05738192A patent/EP1748705B1/de not_active Not-in-force
- 2005-05-10 CN CN2005800158315A patent/CN1953669B/zh not_active Expired - Fee Related
-
2012
- 2012-09-14 JP JP2012203513A patent/JP2013047227A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP5145035B2 (ja) | 2013-02-13 |
| ES2351701T3 (es) | 2011-02-09 |
| DE602005024128D1 (de) | 2010-11-25 |
| JP2013047227A (ja) | 2013-03-07 |
| KR20070011515A (ko) | 2007-01-24 |
| JP2008500376A (ja) | 2008-01-10 |
| WO2005110122A1 (en) | 2005-11-24 |
| CN1953669B (zh) | 2010-06-16 |
| EP1748705B1 (de) | 2010-10-13 |
| KR101317976B1 (ko) | 2013-10-14 |
| CN1953669A (zh) | 2007-04-25 |
| EP1748705A1 (de) | 2007-02-07 |
| US20080070980A1 (en) | 2008-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE484201T1 (de) | Verwendung von beta-cryptoxanthin | |
| DE502004001052D1 (de) | Verwendung von polysilazan zur herstellung von hydrophob- und oleophobmodifizierten oberflächen | |
| ATE472317T1 (de) | Kosmetische verwendung von molkeproteinmizellen | |
| DK1844074T3 (da) | Humane antistoffer og proteiner | |
| DE602005012555D1 (de) | Künstliches protein zur absoluten quantifizierung von proteinen und verwendungen davon | |
| DE602004021037D1 (de) | Phosphororganische indazolderivate und deren verwendung als proteinkinaseinhibitoren | |
| EA200901313A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| DE60314500D1 (de) | Diaminopyrimidine und deren verwendung als angiogenesehemmer | |
| DE60325761D1 (de) | Diaminotriazole derivate und deren verwendung als protein kinase inhibitoren | |
| ATE531382T1 (de) | Behandlungsmethoden von entzündungskrankheiten mit spezifisch an menschliches angiopoietin-2 bindenden wirkstoffen | |
| DE50207852D1 (de) | Verwendung von fettalkoholethoxylaten als penetrationsförderer | |
| ATE498324T1 (de) | Verwendung von säuglingsnahrung mit reduziertem proteingehalt | |
| ECSP077222A (es) | Anticuerpos monoclonales humanos contra interleucina-4 humana (il-4) | |
| DE602006000511D1 (de) | Dermatologische verwendung von proteinen aus milch | |
| DE60207053D1 (de) | Rekombinante gelatineartige proteine zur verwendung als plasmaexpander | |
| ATE466080T1 (de) | Formulierungen und verfahren zum denaturieren von proteinen | |
| ATE424724T1 (de) | Verwendung von n-arylhydrazinderivaten für die bekämpfung von schädlingen in und an tieren | |
| DE602006019849D1 (de) | Proteinspaltungsverfahren und verwendung davon | |
| ATE445402T1 (de) | Neue verwendung von pde5-hemmern | |
| DE602004032465D1 (de) | Referenzstandard zur charakterisierung von rosuvastatin | |
| ATE506370T1 (de) | Reagenzien und verfahren zur bildung von disulfid-bindungen und glykosylierung von proteinen | |
| ATE527280T1 (de) | Fluoreszentprotein und chromoprotein | |
| DE602005013650D1 (de) | Proteinhydrolysat zur behandlung von müdigkeit | |
| DE60325496D1 (de) | Verwendung von dihydroimidazolonen zur behandlung von epilepsie bei hunden | |
| DE60326773D1 (de) | Peptid-deformylase-hemmer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |